Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Operating Leases (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Operating Leases for 3 consecutive years, with $368000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 1433.33% to $368000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $368000.0 through Dec 2025, up 1433.33% year-over-year, with the annual reading at $368000.0 for FY2025, 1433.33% up from the prior year.
  • Operating Leases hit $368000.0 in Q4 2025 for Connect Biopharma Holdings, down from $445000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $594000.0 in Q1 2025 to a low of $24000.0 in Q4 2024.
  • Historically, Operating Leases has averaged $355166.7 across 3 years, with a median of $406500.0 in 2025.
  • Biggest five-year swings in Operating Leases: tumbled 86.67% in 2024 and later skyrocketed 1433.33% in 2025.
  • Year by year, Operating Leases stood at $180000.0 in 2023, then crashed by 86.67% to $24000.0 in 2024, then surged by 1433.33% to $368000.0 in 2025.
  • Business Quant data shows Operating Leases for CNTB at $368000.0 in Q4 2025, $445000.0 in Q3 2025, and $520000.0 in Q2 2025.